Kevin Grogan has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharmaceutical companies, he joined Scrip as Managing Editor, Europe, Commercial in the summer of 2017.
Covering all aspects of the pharma industry, Kevin has interviewed pretty much all the leading figures in the sector, both in the UK and globally. A regular attendee at financial and medical conferences worldwide (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss events in the pharmaceutical industry.
Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at the Catholic weekly newspaper The Universe and also contributed articles to the likes of The Independent and the Manchester Evening News on football.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Kevin Grogan
The Swiss major has new data on its SMA gene therapy which has been found not to be the cause of the death of a six-month-old patient earlier this year.
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.
The German group believes its €2bn target of pipeline sales by 2022 is achievable. It is hoping for a healthy contribution from rare lung cancer drug tepotinib.
Presentations at ECTRIMS highlight the recently approved pill's effects on disability and cognition.
Ahead of a 12 September PDUFA date for irritable bowel syndrome, the US firm's tenapanor has also succeeded in a second trial as a treatment for hyperphosphatemia.